Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 439Neoplasms 364Breast Neoplasms 261Colorectal Neoplasms 245Neoplasm Metastasis 217Melanoma 210Leukemia, Myeloid, Acute 188Multiple Myeloma 187Pancreatic Neoplasms 183Ovarian Neoplasms 181Recurrence 175Prostatic Neoplasms 161Lymphoma, Non-Hodgkin 142Stomach Neoplasms 133Squamous Cell Carcinoma of Head and Neck 128Lung Neoplasms 126Lymphoma 121Carcinoma, Hepatocellular 117Carcinoma, Renal Cell 102Triple Negative Breast Neoplasms 100Leukemia, Lymphocytic, Chronic, B-Cell 99Glioblastoma 98Advanced Solid Tumor 94Leukemia 93Small Cell Lung Carcinoma 91Lymphoma, Large B-Cell, Diffuse 90Head and Neck Neoplasms 87Advanced Solid Tumors 85Endometrial Neoplasms 81Myelodysplastic Syndromes 78

Interventions

seclidemstat 1Topotecan 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Histiocytoma, Angiomatoid Fibrous × Clear all
NCT05266196 2023-08-01

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Salarius Pharmaceuticals, LLC

Phase 1/2 Unknown
10 enrolled
Sarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Myoepithelioma, Sarcoma, Ewing, Liposarcoma, Myxoid, Sarcoma, Clear Cell, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡